Tempus AI announced its acquisition of Paige, an AI company specializing in digital pathology, for a consideration of $81.25 million. This strategic move allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in the digital pathology sector.
Paige is recognized as the owner of the first FDA-cleared AI application in pathology, offering solutions and services that leverage AI for enhanced diagnostic capabilities. This acquisition is expected to significantly accelerate Tempus’s efforts to build the largest foundation model in oncology.
The integration of Paige's expertise and technology into Tempus's platform will enhance its AI-driven precision medicine solutions. This expansion into digital pathology represents a new domain for Tempus, broadening its multimodal data capabilities and strengthening its position in the healthcare AI market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.